Cevostamab

Cevostamab is an investigational agent whose form is not stated in the registry developed by Hoffmann-La Roche. The sponsor describes its target as FcRH5, which OnCo does not yet have a target page for. ClinicalTrials.gov describes the intervention as: Participants will receive cevostamab IV as per the schedule given in the protocol. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07555938 (Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma), in multiple myeloma. The largest, NCT07555938, plans to enrol 380 participants with primary completion expected 2028-10-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.